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Background: A published clinical prediction score indicated that a unilateral adrenal adenoma and either
hypokalemia or an estimated glomerular filtration rate of 100 ml/min/1.73 m2 was 100% specific for unilateral
primary aldosteronism. This study aimed to validate this score in a separate cohort of patients with primary
aldosteronism.
Methods: A review of patients with primary aldosteronism from June 2005 to July 2013 at a single center’s
hypertension clinic. One hundred twelve patients with primary aldosteronism underwent successful adrenal vein
sampling and the 110 patients with full data available were included in the final analysis. Adrenal vein sampling
was performed all patients desiring surgery by the simultaneous collection of sample prior to and 15 minutes after
a cosyntropin infusion with a 3:1 aldosterone/cortisol ratio diagnosing unilateral primary aldosteronism. The derived
score was applied to the cohort. Sensitivity and specificity were calculated for clinical prediction score of ≥5 points.
Results: There were 64 patients found to have unilateral primary aldosteronism and 48 had bilateral disease. A
score ≥5 points had 64% sensitivity (95% confidence interval, 51–76) and 85% specificity (95% confidence interval,
71–94) for unilateral disease. Four patients had lateralization of primary aldosteronism to the side contralateral to
the adenoma.
Conclusions: The 100% specificity of the score for the unilateral origin of primary aldosteronism was not validated
in this cohort with a score of ≥5 points. At best, a high score in this prediction rule may be an additional tool for
helping to confirm a decision to offer patients adrenal vein sampling.Background
Primary aldosteronism (PA) is the most common cause
of secondary hypertension with a 4-20% prevalence [1].
Using population-based screening, the underlying path-
ology is most frequently bilateral adrenal hyperplasia
followed by unilateral aldosterone producing adenoma;
less often, unilateral hyperplasia is also found [2]. Diagno-
sis involves screening patients with an aldosterone renin
ratio (ARR) followed by a confirmatory test, if appropriate
[3,4]. Subsequently, computerized tomography (CT) of
the adrenal glands can identify an adenoma as a source
of aldosterone excess, though CT lacks sensitivity and
specificity for unilateral PA [5]. It has been suggested* Correspondence: Gregory.kline@albertahealthservices.ca
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unless otherwise stated.that PA patients less than 40 years of age with a ≥1 cm
unilateral adrenal adenoma could be directed to unilateral
adrenalectomy without adrenal vein sampling (AVS) [5].
This approach applies to just 10% of patients with PA [6].
Those over 40 years of age with an adenoma or those with
no imaging findings would be directed towards AVS to
distinguish between unilateral and bilateral PA [3]. How-
ever, issues with AVS exist including lack of availability;
technical procedural performance issues, especially when
performed at lower volume centres; and possible risk of
complications [7,8].
A need exists, then, for a clinical prediction score (CPS)
that predicts unilateral PA for a larger proportion of pa-
tients. A published CPS found 100% specificity for the
identification of unilateral aldosterone excess in patients
with confirmed PA in a retrospective analysis of pa-
tients 87 patients [6]. The predictive factors includedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(potassium ≤3.5 mmol/liter); and evidence of aldosterone-
induced hyperfiltration with an increased estimated glom-
erular filtration rate (eGFR), using the modified diet in
renal disease equation [9]. Each factor contributed a
weighted number of points to the overall CPS with a
maximum of 7 points for a patient with all three fea-
tures (Table 1). A CPS of ≥5 was associated with 100%
specificity for unilateral PA [6]. If this CPS were to be
validated and the 100% specificity confirmed, practi-
tioners would be able to confidently refer 30% of patients
with PA and an imaged adenoma for surgical management
without having AVS [6]. Two subsequent analysis of this
CPS applied to different databases could not replicate the
100% specificity with performance characteristics of 38.8%
specificity and 88.5% specificity [10] and sensitivity of 46%
and a specificity of 80% [11] . The present study aimed to




The study population was derived from the AVS data-
base of a single, dedicated endocrine hypertension clinic
with uniform screening for PA in all patients. Demo-
graphic, diagnostic and clinical outcome data from this
cohort have been previously published [12], although the
present study now includes updated patient data com-
prising June 2005 to July 2013. A single interventional
radiologist performs the AVS, with success rates of 97%
[13]. This database and its analysis have been approved
by the University of Calgary Conjoint Health Research
Ethics Board.
Collected data and diagnostic criteria
At the initial consultation, clinical features systematically
recorded included age, sex, body mass index, ethnicity,
medications, and the measurement of blood pressure (BP)
with the patients sitting quietly in a room after a 5-minute
rest using the BpTRU measurement system (Coquitlam,
BC, Canada).Table 1 Clinical prediction score to predict lateralized
AVS (ref. [6])
Item Points
Typical Conn’s adenoma on imaging 3
Hypokalemia <3.5 mmol/liter 2




Total score (max 7)All patients had measurement of ARR while seated in
an upright position before 1000 h. Antihypertensive
medications are not routinely stopped with the excep-
tion of mineralocorticoid antagonists, which are stopped
for 6 weeks prior to testing [14]. The ARR is calculated
from both lab values, using 0.1 ng/ml/h to avoid over-
inflation of the ARR.
At our institution, an ARR greater than 550 (aldoster-
one in pmol/l and renin activity in ng/ml/hour; equiva-
lent to cutoff of 15 when aldosterone expressed in ng/dl)
has been used to identify patients with PA. Formal con-
firmatory testing has not been used in our unit since
2005; 90% of our current PA cohort are encompassed by
an ARR of more than 4 times the upper limit of normal
[4,15] or a suppressed renin (less than 0.1 ng/ml/hr)
while on an angiotensin converting enzyme inhibitor or
an angiotensin receptor blocker [16]. There has not been
a demonstrable increase in false positive PA diagnoses
on pathology when our institution’s data has been
reviewed [17].
Adrenal imaging and AVS are sequentially performed
to characterize PA as either unilateral or bilateral. At
our institution, AVS is only performed on PA patients
who are considered to be surgical candidates and who
desire surgery, consistent with a consensus published ap-
proach [18]. Thus, PA patients with complex, serious
medical comorbidities are excluded from further investi-
gation and this analysis. All surgical decisions are made
based on AVS and imaging; no patients went to surgery
without AVS being done. All patients selected for AVS
had a 3 mm cuts CT scan of the adrenal glands with a
classic adenoma defined as a nodule of 8 mm or greater
and a normal contralateral adrenal contour [19]. Bilat-
eral nodules, possible hyperplasia and nodules less than
8 mm were considered as lacking a classic adrenal aden-
oma. Hypokalemia was corrected using oral potassium
supplements prior to AVS. Whenever possible, AVS was
performed using non-dihydropyridine calcium channel
blockers and alpha blockers for BP control although this
was not always feasible due to hypertension concerns [20].
The AVS protocol as previously published included
simultaneously collected baseline adrenal vein and infer-
ior vena cava-cortisol and aldosterone samples followed
by a 250 μg cosyntropin bolus and subsequent 25 ml infu-
sion of 250 μg cosyntropin in 1000 ml D5W over 15 minutes
[21] A second set of samples was then collected from each
site. Adequate adrenal vein cannulation was defined as a se-
lectivity index (adrenal/inferior vena cava-cortisol ratio) >3:1
for either baseline or stimulated results. Unilateral PA was
diagnosed when the lateralization index (LI) from the dom-
inant adrenal was > 3:1 compared to the non-dominant ad-
renal results on either the baseline or stimulated samples. In
virtually all cases, lateralization was consistent on both base-
line and stimulated samples [22].
Figure 1 Patient selection and distribution.
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radioimmunoassay (RIA) using the Siemens Coat-A-Count®
aldosterone assay (Siemens Healthcare Diagnostics, Tarry-
town, NY). Mean interassay imprecision coefficients of vari-
ation were 13.0%, 6.8% and 6.8%, for aldosterone levels of
4.2 ng/dl, 24 ng/dl and 58.1 ng/dl, respectively. Dilutions
were performed for the measurement of aldosterone levels
greater than 72.2 ng/dl. Plasma renin activity (PRA) was
measured by RIA of angiotensin I in the presence of re-
agents that inhibit angiotensin I-converting enzyme and
angiotensinases using the GammaCoat® Plasma Renin Activ-
ity I125 RIA Kits (DiaSorin, Stilwater, MN). Mean inter-assay
imprecision coefficients of variation were 11.1%, 7.8%,
and 13.4% for PRA of 0.95 ng/ml/h, 5.17 ng/ml/h, and
21.2 ng/ml/h, respectively.
Plasma cortisol was measured by an automated elec-
trochemiluminescence assay on the Roche Elecsys E170
(Roche Diagnostics, Mississauga, ON, Canada). Mean intra-
assay imprecision coefficients of variation were 6.4%, 4.0%,
and 3.2% for cortisol levels of 4 μg/dl, 22.6 μg/dl, and
32.9 μg/dl respectively. An initial dilution of 1:10 is auto-
performed by the on-board instrument algorithm. When ne-
cessary a further off-line 1:25, 1:50 or 1:100 is selected and
performed using manufacturers’ universal diluent to obtain
an end-point level which is reported.
Patients with bilateral AVS results under the age of 40
undergo a dexamethasone suppression test to screen for
glucocorticoid-remediable aldosteronism; suppression of
plasma aldosterone by >80% determines who is referred
for formal genetic testing [23]. From September 2009
until present, serum creatinine was measured within one
week prior to AVS. Previously, it was measured within
6 months of AVS. Surgical candidates (unilateral PA)
who agreed to surgery were referred for adrenalectomy.
Postoperatively, the patients returned to the endocrine
hypertension clinic for post-operative ARR measures
and clinical reassessment, titrating any residual antihy-
pertensive medications as needed. In general, patients
in the clinic are offered follow-up visits at 4- to 6-week
intervals during this period. Hypertension cure was de-
fined as a BP of less than 140/90 mm Hg on no anti-
hypertensive medications. Marked clinical improvement
was defined as control of BP to less than 140/90 mmHg on
fewer antihypertensive medications than at presentation.
Statistical analysis
Unilateral and bilateral PA groups were defined using
standard descriptive statistics, reporting group medians
and intraquartile ratios (IQRs). Between-group continu-
ous variables were analyzed using a two-tailed Mann–
Whitney U Test for non-parametrically distributed data.
Categorical data was compared by Chi-squared test with
alpha set at 0.05. Each subject had a CPS calculated
retrospectively, based upon the CPS of Küpers et al. [6].Those with a CPS of ≥5 out of 7 were examined to de-
termine whether the actual AVS results and outcomes
confirmed unilateral PA. A receiver operating character-
istic (ROC) curve was calculated to determine the over-
all sensitivity and specificity of the predictive rule to
predict unilateral PA with special attention to the cut-off
of ≥ 5 points. A separate analysis applied this CPS to
those with a classic unilateral adenoma, as this group
of patients would be the only group able to obtain a
CPS ≥5 and where clinicians would have to consider
whether or not to perform AVS prior to surgery. All
computations were performed using Analyse-it software,
2011, (Analyse-it Software, Leeds, UK) except ROC
curve analysis which was done with MedCalc 12.7
(MedCalc Software, Mariakerke, Belgium).
Results
Patients
The cohort consisted of 116 patients with PA. AVS was
successful in 112 patients (96.5%), and full data exist for
110 of these 112 patients (Figure 1). Characteristics of
the AVS cohort are presented in Table 2. An ARR was
greater than 4 times the upper limit of normal in 78
(71%) of 110 patients [15]. Of the remaining 32 subjects,
23 had an elevated ARR while an ACE inhibitor or an
angiotensin receptor blocker was being used for blood
pressure control [16]. Unilateral PA was diagnosed by
AVS in 64 patients (58%) and 53 elected ultimately to
have surgical therapy. On surgical pathology, 34 had
discrete adrenocortical adenoma, 14 had discrete aden-
oma with surrounding adrenal hyperplasia, and 5 had
pure unilateral adrenal hyperplasia. Of the 37 patients
who underwent postoperative ARR, 36 had an undetect-
able PAC or a normal ratio (ARR <550). The one patient
with a persistently high post-operative ARR had an adre-
nocortical adenoma on pathology while also having a
nodule on the contralateral adrenal gland, presumably
representing a second aldosterone producing adenoma
and an initial false positive AVS. Excluding the 3 patients
Table 2 Baseline characteristics of included patients
Lateralized AVS Nonlateralized AVS P value
n 64 46
Age, years 49 [40,58] 48 [39,55] 0.69
BMI (kg/m2) 29.0 [25.7,33.8] 30.9 [25.5,33.7] 0.89
Percentage of male subjects (%) 39 (61%) 20 (44%) 0.11
Systolic BP at presentation (mm Hg) 149 [136,161] 145 [131,158] 0.55
Diastolic BP at presentation (mm Hg) 90 [81,100] 91 [80,100] 0.90
Initial plasma aldosterone (ng/dl) 19.0 [14.7,29.4] 13.9 [9.0,17.7] 0.002
Aldosterone renin ratio (normal <15) 128 [47,266] 104 [50,142] 0.10
Plasma renin activity (ng/mL/h) 0.14 [0.1,0.32] 0.11 [0.1,0.25] 0.38
Initial serum K+ (mmmol/liter) 2.9 [2.6,3.5] 3.7 [3.2,3.8] <0.0001
Serum potassium < 3.5 mmol/liter (%)
mmmmmmolmmol/liter (%)
49 (77) 22 (46) 0.002
eGFR (ml/min/1.73 m2) 87.1 [67.8,96.5] 80.5 [67.9,98.3] 0.73
Adenoma ≥8 mm on CT (%) 46 (72) 16 (36) <0.0001
Reported values represent number (percentage) or median [p25, p75]. n, Number of observations.
Venos et al. BMC Endocrine Disorders 2014, 14:94 Page 4 of 7
http://www.biomedcentral.com/1472-6823/14/94lost to long term follow-up, 23 patients (44%) achieved
clinical hypertension cure and sustained BP control of
less than 140/90 mmHg and 28 patients (54%) achieved
a marked improvement with a reduction of medications
and control of BP < 140/90 mmHg.
Mean clinical observation post AVS was 17.4 (IQR 1–60)
months for the entire population and 8.9 months (IQR
1–49) post-operatively for those having surgery. The
non-lateralized group had a median LI pre-cosyntropin
stimulation of 1.50 (IQR 1.2, 2.4) and post-cosyntropin
stimulation of 1.3 (IQR 1.1-1.6) at baseline and post-
cosyntropin infusion. The lateralized group had a median
LI (LI) of 11.8 (IQR 4.2-23.5) and 12.3 (IQR 5.5-30.8) in
comparison. When patients with unilateral PA were com-
pared with those who had bilateral PA, the unilateral pa-
tients had higher initial aldosterone, lower initial serum
potassium, and higher proportion of unilateral classic ad-
enoma on CT imaging (all p < 0.01).
Retrospective application of the clinical prediction score
to all patients
In our database, of 48 patients with a CPS of ≥5, 7 failed
to show lateralization with AVS (Table 3). Thus, the CPS
of ≥5 had a sensitivity of 64% (95% CI 51–76) and a spe-
cificity of 85% (95% CI 71–94). The positive predictiveTable 3 2×2 table using clinical prediction score of ≥5,
applied retrospectively to the derivation cohort
Lateralized AVS Nonlateralized AVS
Score≥ 5 41 (64) 7 (15)
Score < 5 23 (36) 39 (85)
Total 64 46
Patients (%) reported.value was 85%. A CPS of ≥6 had a sensitivity of 39%
(95% CI 27–52) and a specificity of 96% (95% CI 85–100).
The ROC curve is shown in Figure 2. The area under the
ROC curve was 0.77 (95% CI 0.68-0.84). Of the 7 patients
with CPS ≥5 who did not show lateralization on AVS, all
had a classic adenoma (mean size 19 mm) and all had
hypokalemia. Six were over 40 years of age. The mean
AVS baseline LI was 2.1 while the mean post-cosyntropin
LI was 1.7. The single patient from this subset who was
younger than 40 years old had a LI of 4.5 at baseline,
though this decreased to 1.5 post-cosyntropin stimulation.
We cannot exclude the possibility that this single subject
actually does have unilateral PA, masked by ACTH use
during AVS [24].
In addition, of the 48 patients with a CPS ≥5, 4 patients
had imaging showing an adrenal adenoma on the opposite
adrenal from the side of AVS-defined unilaterality.Figure 2 ROC curve of the clinical prediction score from validation
cohort.
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and the 4 discordant positives, 11 of 78 (15%) of pa-
tients would have had unnecessary surgery or the
wrong adrenal gland removed using this CPS. Of the
23 patients with unilateral PA by AVS, but a CPS <5
(Table 3), 14/23 had eukalemia, 22/23 had an eGFR
less than 100 ml/min/m2, and 16/23 had no findings
of classic adenoma of CT imaging, representing 36% of
the entire unilateral PA group. When patients under
40 years of age with a unilateral adenoma (≥10 mm) were
assessed for this criteria’s performance characteristics, it
was found to have a sensitivity of 94% (95% CI 70–100)
and a specificity of 75% (43–95), although this subanalysis
only comprised 28 subjects. The 3 patients with an ad-
renal adenoma (11 and 13 mm) but a nonlateralized AVS
all had an ARR above 4 times the upper limit of normal
and 2 of 3 had hypokalemia. One of these patients was de-
scribed above: baseline LI of 4.5 decreasing to 1.5 post-
cosyntropin stimulation (possible lateralized PA, treated
as nonlateralized on the basis of post cosyntropin testing
LI < 3). The other two patients had baseline LIs of 2.7 and
1.7, and post-cosyntropin stimulation LIs of 2 and 1.2.
Discussion
We aimed to determine the validity of the CPS devel-
oped by Küpers et al. in our own independent cohort of
PA patients. With our validation cohort, the CPS of ≥5
had a sensitivity of 64% (95% CI 51–76) and a specificity
of 85% (95% CI 71–94), all as defined by AVS but still
not accounting for the few cases where imaging and
AVS findings are discordant. This specificity of this CPS
is similar to that reported previously, yet does not ap-
proach the 100% specificity that might be necessary for
routine clinical use in surgical decision-making. With
our total unilateral disease prevalence of 58%, this CPS
had a positive predictive value of 85%. A CPS of ≥6 did
perform better with a specificity (96%) approaching 100%.
If this cut point were used, then the CPS would apply to
approximately 20% of patients with PA. This point has not
been previously emphasized; although few patients may
achieve such a high score, for those who do, a near-
perfect specificity may well add significantly to the clinical
confidence in a lateralized diagnosis.
A further concern is demonstrated by 4 patients with
a CPS of ≥5 who had AVS lateralization contralateral to
the side of the adenoma, leading to a total of 11 appar-
ently unilateral PA patients having surgery that would be
unnecessary when one also includes the 7 clearly bilat-
eral PA patients who also had a CPS ≥5. The derivation
cohort had just one patient that had these characteristics
[6], as did one of the validation cohorts [11]. These
cases, while few, are a sobering caution that omission of
the AVS step does carry a small risk of misclassification
and inappropriate management. Interestingly, we alsofound less than 100% specificity (75%) for unilateral
disease in patients under 40 who also had a typical ad-
enoma of ≥10 mm, which is also contrary to the find-
ings of the derivation cohort and others [5,6,11]. This
may reflect differing biochemical definitions as to what
constitutes “unilateral” AVS or a differing size defin-
ition of an adrenal nodule. Centers using more strict
or more lenient lateralization indices may well show
apparent differences in the proportions of patients
deemed unilateral and verification will be limited to
those who actually undergo adrenalectomy.
It is increasingly recognized that PA can have multiple
different molecular etiologies including various genes
and ectopic hormone receptors [25,26]. It would there-
fore be expected that there may well be significant vari-
ation in disease presentation, diagnostic features and
possibly response to therapy according to such differing
causes and modified by variables that influence pene-
trance such as age, sex and ethnicity. In the future, more
sophisticated molecular studies of confirmed PA cases
may permit a better understanding of the apparent dif-
ferences between PA study populations.
Study strengths
The approach to diagnosis and therapy were uniform for
the duration of the database. In addition, CT of the ad-
renal glands and AVS were performed on all patients
who were considering surgery, which eliminates any po-
tential bias due to selective use of AVS and ensured that
the CPS could be applied to every patient in our data-
base. Our centre has a very low rate of AVS failure en-
suring broad inclusion of a high number of patients and
the reliability of the procedure [12]. Finally, standardized
longitudinal assessment of patient-level outcomes such
as BP readings, number of medications, follow-up ARR
after surgery, and surgical pathology confirmed a clinical
biochemical diagnosis of PA in the cohort that under-
went surgery [17].
Study limitations
As will be true of all studies comparing a test performed
at different endocrine units, differences between study
cohorts always limit the generalization of any findings to
other centres where patients and the diagnostic ap-
proaches can vary. We were able to analyze 110 patients
in our cohort compared to 87 in the derivation cohort
and 78 in the other validation cohort. Our cohort fea-
tured a high proportion of patients with unilateral PA
(58%), which is a comparable proportion to the 56% in
the derivation cohort. This higher proportion than in
other populations likely reflects referral bias as well as
reflects the practice where an increasing proportion of
lateralized patients is found when AVS is performed rou-
tinely. As well, it is possible that routine clinical decision
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high risk features for further investigation.
Our diagnosis of PA is based on the presence of an el-
evated ARR ratio without the requirement of a con-
firmatory test prior to CT scanning and AVS and this
certainly reflects a practice that differs from most other
endocrine hypertension units. Other units may also meas-
ure ARR under different conditions and use different cut-
off values for definition of PA. This diagnostic variation
might well affect the final prevalence of unilateral PA in
different centers [27,28]. In our cohort, surgical manage-
ment based on our diagnostic criteria lead to surgical cure
or improvement of hypertension in all but one of our
patients (thought to have bilateral APA based on post-
operative biochemistry and imaging). Ideally all sub-
jects should have had a post-operative ARR measured
to confirm resolution of PA rather than depending
upon blood pressure and pathology alone. While one
could consider possible false positive PA case ascer-
tainment, the diagnostic agreement between our approach
and that of the derivation cohort was remarkably high
(56% and 58% unilateral PA). Other units with a lower
prevalence of unilateral PA might find very different speci-
ficity for the CPS.
The CT scans were read by the institution’s radiolo-
gists and not subjected to a blinded panel review. It is
possible that a blinded, multi-reviewer panel could have
come up with differing interpretations of the CT images
which could affect the subject classification and score al-
though the CPS performance could be either better or
worse than estimated here. Our pragmatic use of CT
scans as reported by a clinical radiologist may actually
be an asset in that it reflects routine use of imaging data
in a functional endocrine hypertension unit, in the same
way that the CPS is intended to be used.
Compared to the derivation cohort, our cohort shared the
finding of increased hypokalemia, increased aldosterone,
and the higher proportion of patients with an adenoma in
the lateralized AVS group compared to the non-lateralized
AVS group. Unlike the derivation cohort, there were no dif-
ferences in eGFR between groups. This could represent a
type 2 error from small numbers. However, this would be
unlikely to affect the specificity of the CPS as all patients
who had a CPS of ≥5, but did not have a lateralized AVS
had hypokalemia and an adenoma.
The clinical prediction score itself has several import-
ant limitations to widespread use, notably the use of
GFR as a predictive value. A person with PA may have
widely variable measures in GFR depending upon age,
concomitant medication use and duration of aldosteron-
ism, all of which can influence a single measure of GFR
without reference to the laterality status. A second PA
subtype prediction rule has also recently appeared in the lit-
erature [29] which purports to show that the combinationof plasma aldosterone, potassium and post-captopril ARR
may help predict unilaterality. However, this has also been
generated using a small sample size and will also need exter-
nal validation attempts. A multi-national standardized PA
database is likely necessary to have adequate power for the
discovery of all significant clinical factors that may ultimately
form a more accurate and generalizable clinical prediction
rule.Conclusions
Clinical prediction scores are an important tool in clin-
ical decision making, though they require validation and
an impact analysis to determine whether they should be
applied broadly [30]. Despite the promise of this CPS to
include a higher proportion of patients who could
proceed directly to surgery without AVS, the specificity
was not sufficiently high to exclude the possibility of
an unnecessary surgery. The CPS performed less well
when it was applied to those already known to have a
unilateral adenoma on imaging as it would be used in
clinical practice. Overall, 15% of patients would have
unnecessary or unhelpful surgery if this CPS was ap-
plied and surgery undertaken without AVS. The CPS
may be useful to help select patients that should in-
deed have AVS with a high probability of finding uni-
lateral disease. Thus, this CPS in its current form may
be complimentary to AVS rather than a replacement
for AVS. Despite the limitations of AVS, for patients
who desire surgical therapy of PA, AVS should still be
undertaken to confirm surgical suitability and planning.
Endocrine hypertension specialty units should consider
local validation of the CPS before clinical implementation.Consent
Written informed consent was obtained from our pa-
tients, which include their clinical data for the publica-
tion of this report.
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